Language:
  
[Sign in] [Register]   

EIAab logo

EIAab news detail, please contact eiaab@eiaab.com if you have any questions about online orders and payment.
Index > >
New progress in hepatitis e vaccine development
Update time:2018-01-31 00:08:48   【 Font: Large  Medium Small

        The viral hepatitis caused by hepatitis virus is divided into a, b, c, d and e. Hepatitis e, also known as amyl hepatitis, is an acute viral hepatitis caused by RNA viruses, which is the main cause of severe liver problems.

         Hepatitis e is spread mainly through contaminated water and person-to-person contact, and is easily popular in areas with poor sanitation. According to the world health organization, about 20 million people are infected with the hepatitis e virus each year, of which more than 3 million people develop acute hepatitis e, and almost 57, 000 die. Among them, for pregnant women, the death rate of hepatitis e is higher. The average person is infected with the disease, with a death rate of about 1 to 3 percent, and a fifth for pregnant women.

        on December 9, 2011, Xiamen university professor NingShao  team developed hepatitis e vaccine for a class of new drug certificate issued by the state food and drug administration approval documents and production, is the first complete international hepatitis e vaccine clinical trials. The principle of the hepatitis a vaccine is the use of giant coli expression system to express hepatitis e virus capsid protein, then after purification of multiple capsid protein composition is a highly complex structure virus-like particles, has a large advantage of immune epitope, so after the immune body, can stimulate the body to produce a lot of blocking antibodies against hepatitis e virus invasion. The virus-like particles are produced by genetic engineering recombinant technology. The products contain no hepatitis e virus and have high safety.

        After a 4.5 year follow-up, the researchers found that they still had antibodies against the hepatitis e virus. It is shown that the hepatitis e vaccine can produce good lasting immunity and significantly reduce the risk of hepatitis e.

         The U.S. centers for disease control and prevention Eyasu Teshale Dr "hepatitis e vaccine could be the spread of the disease prevention and control hepatitis e and new tools", and put forward "is given based on the study of hepatitis e vaccine lasting protection of evidence, now to the realization of hepatitis e vaccine in the field of public health".

         Reference: the world's first hepatitis e vaccine, developed by Jun Zhang Xiamen university, has been proved to be durable and effective

 

by EIAab organize the information.
Hot Genes
ALCAM ACE KSR2 ASPRO C19orf80 Gdf5 Trap1a Atf2
Top Searches
Ubiquitin ELISA Ubiquitin-protein ligase Asprosin metalloproteinase TRAP1A Tumor necrosis vitamin d
Why choose EIAAB
Our products have been quoted by many publications in famous journals such as Cell; Cell Metabolism; Hepatology; Biomaterials.more
Further Information
About us Protein center Bank account Distributors Terms & Conditions Career eiaab.cn

Copyright & copy www.eiaab.com2006-2016 All Rights Reserved    EIAab         Email:eiaab@eiaab.com

Twitter